


CRISPR-Enabled CAR-T Cell Therapy Landscape

A cited research-leadership and momentum snapshot built from current public PubMed records.



Decision use

This packet shows the work Tensorust can deliver for a portfolio team, corporate strategy group, or therapeutic-area owner: a traceable starting point for research diligence, expert mapping, and topic monitoring. It is a real source-limited analysis, not a product mockup.

What the public record helps surface	What this packet does not claim
- Which researchers and institutions repeatedly appear in the current record - Which subtopics dominate the retrieved literature - Where research activity is visible by year - Which records should be opened first	- Investment, clinical, or commercial conclusions - Citation-weighted influence or person identity resolution - Complete coverage of every paper, trial, or company - A substitute for clinical, legal, or investment diligence

Source and method


Query: **CRISPR CAR-T cell therapy**. The packet analyzes 600 records published from 2022 through 2026 and retrieved from NLM PubMed. Every cited paper links to its PMID. Research leaders are ranked by recent publication volume in this retrieved set. Generated July 21, 2026.

Tensorust is built for cited, verifiable work from public data. Explore the live engine at tensorust-site.vercel.app.

Research momentum and leadership

Publication volume in the retrieved set is a discovery signal. It is not a measure of clinical authority, influence, or financial relevance.

Publication momentum



Top public research leaders

#	Researcher	Primary public affiliation	Papers
1	Hamadani Mehdi	Medical College of Wisconsin	20
2	Perales Miguel-Angel	Adult Bone Marrow Transplant Service	20
3	Lin Yi	Mayo Clinic	17
4	Shadman Mazyar	Clinical Research Division	15
5	Ahmed Nausheen	The University of Kansas Cancer Center	15
6	Eyquem Justin	University of California	14
7	Ghobadi Armin	Washington University School of Medicine	14
8	Bachanova Veronika	University of Minnesota	13
9	Ruella Marco	University of Pennsylvania	12
10	Müller Fabian	University Hospital of Erlangen	11

Method note: The full paid workflow adds citation weighting, ORCID-led name disambiguation, trial-investigator mapping, competitor filters, and a buyer-defined source scope.

Institution and topic landscape

The tables below are public-record discovery signals that help a team decide where to investigate further.

Leading institutions	Active indexed subtopics
University of Pennsylvania 45 records The University of Texas MD Anderson Cancer Center 43 records Mayo Clinic 39 records Medical College of Wisconsin 35 records Moffitt Cancer Center 27 records University of Minnesota 26 records Stanford University School of Medicine 26 records University of Chicago 25 records	Immunotherapy, Adoptive 414 records Receptors, Chimeric Antigen 318 records T-Lymphocytes 221 records CRISPR-Cas Systems 142 records Mice 137 records Neoplasms 135 records Gene Editing 122 records Cell Line, Tumor 88 records

How this scales for a diligence team

Current delivery	Expansion path
Cited research landscapes, KOL and research-leader maps, Counterfactual claim-evidence briefs, public-source PDFs, and a live topic preview.	Cross-source landscapes joining publications with grants, patents, trials, contracts, company activity, supply risk, and recurring monitoring or alerts.

Cited audit trail

Representative recent public records from the same query set. Each title links directly to the underlying PubMed record.

Cited public record	Why it appears
CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences. PMID 42428992 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strate PMID 42416076 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
[Novel CD6-targeted CAR-T cell therapy for T-cell acute lymphoblastic leukemia: a safe and efficient strategy to prevent fratricid PMID 42409731 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
CRISPR-screen informed engineered T cell therapies. PMID 42292392 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Advanced strategies to enhance the safety, persistence, and efficacy of CAR-T cells in solid tumors. PMID 42245665 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Leveraging CRISPR/Cas9 for optimized adoptive T cell therapies: From molecular engineering to clinical manufacturing. PMID 42190604 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review. PMID 42189068 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Supercharging the metabolic engine: mitochondrial engineering strategies for CAR-T persistence in solid tumors. PMID 42183245 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.
Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights f PMID 42176091 2026	On-topic recent public record in the query set. Open the PMID to inspect the underlying source.

Limits and review standard

The source set is a recent PubMed retrieval, not a systematic review. Records may be incomplete, author names can collide, affiliations may be abbreviated, and publication counts are not citation-weighted. The analysis should be reviewed with the underlying sources before any investment, clinical, legal, regulatory, or partnership decision.

Prepared by Tensorust | cited, verifiable public-data intelligence